Name of Policy: Nursing Mother Guidelines for UTOLEDO Patients Administered Radiopharmaceuticals **Policy Number:** 3364-135-154 **Approving Officer**: Assistant Professor & Deputy **Effective date: 04/10/2025** Clinical Service Chief, Director Radiology Original effective date: 03/1/2019 **Responsible Agent:** Assistant Professor & Deputy Clinical Service Chief, Director Radiology **Scope**: University of Toledo Medical Center Radiology Key words: Nursing, Mother, Guidelines, Radiopharmaceuticals, Administration New policy proposal Minor/technical revision of existing policy X Major revision of existing policy Reaffirmation of existing policy

(A) Policy statement

In addition to the verification of pregnancy status, as required per hospital policy 3364-135-061, the nuclear medicine technologist performing the requested diagnostic or therapeutic exam will verify the breast-feeding status of the female patient prior to administering the radiopharmaceutical(s).

(B) Purpose of policy

To reduce the internal and external radiation exposure to the nursed child, as low as reasonably achievable, received from the nursing mother who is obtaining a nuclear medicine procedure. This potential exposure may be ingested internally from radioactive material excreted into the breast milk, and/or externally emitted from the mother while holding the child. This policy will assist in determining if breast-feeding will be temporarily interrupted, or completely discontinued for procedures involving systemically administered or implanted sources of ionizing radiation.

(C) Scope

This policy is adopted from the *Advisory Committee on Medical Uses of Isotopes (ACMUI) Sub-Committee on Nursing Mother Guidelines for the Medical Administration of Radioactive Materials;* Submitted June 26, 2018. For the following radiopharmaceutical administrations, the recommended timeframe for interrupting or completely discontinuing breast-feeding are as follows:

Radiopharmaceutical	Breast-feeding Discontinuation to Achieve 0.1 Rad to the Limiting Tissue
O-15, Rb-82, Xe-133	No Discontinuation
C-11, N-13	1 Hour
F-18	4 Hours
Ga-68	4 Hours
Tc-99m	24 Hours
Na-I 123	3 Days
In-111	6 Days
Tl-201	4 Days
Ga-67, Zr-89	28 Days
Na-I 124	Stop Breastfeeding
Na-l 131	Stop Breastfeeding*
Lu-177 Octreotate	Stop Breastfeeding
Ra-223 and all alpha emitters	Stop Breastfeeding

^{*} Patients scheduled for therapeutic radioiodine therapy administration should discontinue breast-feeding at least 6 weeks prior to the treatment date and cease completely for that specific child. Breast-feeding may resume normally with any future children that are born.

All patients undergoing a nuclear medicine procedure, and who are currently breast-feeding will also be provided written instructions on the above recommended actions. These instructions will be signed and dated by the patient prior to the administration of the radiopharmaceutical and the information will comply with the requirements per ODH Regulation 3701:1-58-30 *Release of individuals containing unsealed radioactive material* or implants containing radioactive material. These records will be maintained for a minimum of three (3) years.

Approved by:	Policies Superseded by This Policy:
	• None
Nathan Egbert, MD Assistant Professor & Deputy Clinical Service Chief 04/10/2025 Date	Initial effective date: 03/1/2019 Review/Revision Date: 03/1/2019 03/1/2022 03/1/2025 04/10/2025
/s/ Ryan Landis, BSRT (R)(CT) Director, Radiology	Next review date: 04/10/2028
03/24/2025	
Date	
Review/Revision Completed by: Ryan Landis, BSRT (R)(CT)	